Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by carduon Aug 28, 2009 7:57pm
537 Views
Post# 16260213

Also from the Yahoo board

Also from the Yahoo board

Possible warrant income (next 6 months)

Notes:
All dollar values below are in Canadian dollars.
One exercised warrant converts to 1 share.
Warrants can only be exercised on or before their callable or expiry date, whichever comes first.
Following amounts are based on warrants outstanding as of June 30, 2009, from Oncolytics' Q2 Quarterly Report


2,736,200 warrants at $1.80 each = $4,925,160
Callable 30 days following 10 day volume weighted average traded share price > $2.50
Expires Dec 5, 2011

320,000 warrants at $1.80 each = $576,000
Callable 30 days following 10 day volume weighted average traded share price > $2.50
Expires Dec 29, 2009

3,795,000 warrants at $2.40 each = $9,108,000
Callable 30 days following 10 day volume weighted average traded share price > $3.35
Expires May 13, 2012

2,300,000 warrants at $3.50 each = $8,050,000
Expires Feb 22, 2010

Total of above … $22,659,160


Cash from exercise of warrants goes directly to Oncolytics' account, in exchange for shares already accounted for in the Q2 Quarterly Report

Cash resources as of June 30, 2009 … $11,983,352

Bullboard Posts